See every side of every news story
Published loading...Updated

J&J acquires Intra-Cellular Therapies in multi-billion-dollar deal

Summary by ROI-NJ
Johnson & Johnson Thursday announced it has completed its acquisition of Intra-Cellular Therapies Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson Innovative Medicine. “At Johnson & Johnson, we are committed to transforming care for the millions of people worldwide living with neuropsychiatric and neurodegenerative disorders,” said Joaquin Duato, Chairman and CEO, Johnson…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

ROI-NJ broke the news in on Thursday, April 3, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.